But pregabalin, after several regulatory delays, is likely to have broader approval for treating pain than Neurontin does.

FORBES: Generic Competition Won't Fell Pfizer

Generic drug makers are fighting in court to sell their copycat versions of Neurontin, but it's still possible that pregabalin could reach the market first.

FORBES: Generic Competition Won't Fell Pfizer